POVIDONE-IODINE 10% ANTIFUNGAL IS CATEGORY I

POVIDONE-IODINE 10% ANTIFUNGAL IS CATEGORY I for the treatment of athlete's foot, jock itch, and ringworm, FDA told Purdue Frederick in a recent feedback letter. FDA OTC Drug Evaluation Div. Director William Gilbertson, PharmD, told the company that a study submitted in June 1982, "along with the information previously reviewed by the panel, provides adequate evidence of the safety and effectivness of 10% povidone-iodone" in the treatment of fungal infections. Gilbertson said the OTC drug division is therefore recommending the ingredient to Category I in the OTC topical antifungal monograph. Commenting on Purdue Frederick's study of 40 patients with tinea pedis, Gilbertson said the results "clearly indicate the effectiveness of the povidone-iodone solution in the management of dermatophytosis." He stated that after four weeks the solution "cleared 68.4% of the patients while the solution without povidone-iodine cleared 30%. These cure rates were sustained to four weeks post therapy and the difference is statistically significant (p<0.05)." FDA commented that a "significant number of cases" in Purdue Frederick's study were culture positive for T. rubrum, "which is considered to be the 'base' organism for evaluation of the effectiveness of a drug used for athlete's foot." Gilberston said the agency "agrees with the panel that a drug shown to be effective in the treatment of athlete's foot will also be effective in jock itch and ringworm because the infecting organisms of these conditions are representative of the same group as the organisms causing athlete's foot and have been shown to be susceptible to the same antifungal drugs."

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By 

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.